FDA Clears Shoulder Innovations' N-22 Humeral Head for Metal-Sensitive Patients
SI sits 78% above its 52-week low of $10.92.
Summary
Shoulder Innovations received FDA 510(k) clearance for its N-22 Humeral Head, a titanium implant for patients with metal hypersensitivity, and immediately launched it commercially. This is the second product in the company's metal-sensitive line, complementing the N-22 Glenosphere cleared in January 2026. The clearance expands the company's addressable market in shoulder arthroplasty, targeting the 10-15% of patients with metal allergies. The launch follows strong Q2 results with 56% revenue growth and a $50M credit facility secured in June, indicating continued commercial momentum. Watch for initial sales uptake and surgeon adoption in the coming quarters.
At the time of this announcement, SI was trading at $19.48 on NYSE in the Life Sciences sector, with a market capitalization of approximately $397.9M. The 52-week trading range was $10.92 to $24.60. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: PR Newswire.